Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.
S Zhong, D S Sharp, J S Grove, C Bruce, K Yano, J D Curb, A R Tall
Title and authors | Publication | Year |
---|---|---|
Drug designed to raise HDL levels falls down
Karen Honey |
Journal of Clinical Investigation | 2007 |
Familial occurrence of abnormalities of high-density lipoprotein cholesterol
BG Kral, DM Becker |
Journal of Clinical Lipidology | 2007 |
The conscientious judgement of a DSMB – statistical stopping rules re-examined
K Hedenmalm, H Melander, G Alvan |
European Journal of Clinical Pharmacology | 2007 |
Scavenger receptor class B type I polymorphisms and peripheral arterial disease
A Ritsch, G Sonderegger, A Sandhofer, U Stanzl, I Tancevski, P Eller, W Schgoer, A Wehinger, T Mueller, M Haltmayer, JR Patsch |
Metabolism | 2007 |
Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport
JG Robinson, MH Davidson |
Future Lipidology | 2007 |
Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis
J Carlquist, JL Anderson |
Current Opinion in Cardiology | 2007 |
High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench
Y Levy |
Cardiovascular Research | 2007 |
Intrinsic enzymes of high-density lipoprotein
NA Le, MF Walter |
Journal of Clinical Lipidology | 2007 |
Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease?
JA Hamilton, RJ Deckelbaum |
Nature Structural & Molecular Biology | 2007 |
Genome-wide scan for interacting loci affecting human cholesteryl ester transfer protein-induced hypercholesterolemia in transgenic human cholesteryl ester transfer protein F2-intercross rats
VL Herrera, LR Ponce, N Ruiz-Opazo |
Journal of Hypertension | 2007 |
Human Cholestryl Ester Transfer Protein (TaqIB) Polymorphism among Filipinos with Cardiovascular Risk Factors
RG Sy, EM Cutiongco, FE Punzalan, RS Santos, FR Geronimo, RV Tangco |
Journal of Atherosclerosis and Thrombosis | 2007 |
Sex differences in the relation of HDL cholesterol to progression of carotid intima-media thickness: The Los Angeles Atherosclerosis Study
AZ Fan, JH Dwyer |
Atherosclerosis | 2007 |
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
R Krishna, MS Anderson, AJ Bergman, B Jin, M Fallon, J Cote, K Rosko, C Chavez-Eng, R Lutz, DM Bloomfield, M Gutierrez, J Doherty, F Bieberdorf, J Chodakewitz, KM Gottesdiener, JA Wagner |
The Lancet | 2007 |
Partial suppression of CETP activity beneficially modifies the lipid transfer profile of plasma
RE Morton, DJ Greene |
Atherosclerosis | 2007 |
HDL Cholesterol: Physiology, Pathophysiology, and Management
JJ Link, A Rohatgi, JA de Lemos |
Current Problems in Cardiology | 2007 |
Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis:
J Carlquist, JL Anderson |
Current Opinion in Cardiology | 2007 |
Cholesterol ester transfer protein (CETP) and atherosclerosis
D Polk, PK Shah |
Drug Discovery Today: Therapeutic Strategies | 2007 |
The strange case of Dr HDL and Mr HDL: Does a NO’s story illuminate the mystery of HDL’s dark side uncovered by Dr HDL’s drug targeting CETP?
P Duriez, R Bordet, P Berthelot |
Medical Hypotheses | 2007 |
Comprehensive Management of High Risk Cardiovascular Patients
N Kopyt |
Comprehensive Management of High Risk Cardiovascular Patients | 2007 |
High‐Density Lipoproteins: From Basic Biology to Clinical Aspects
CJ Fielding |
2007 |